A Phase 1 interventional study of CM310 in Healthy, sponsored by Keymed Biosciences Co.Ltd. Not yet recruiting at 1 site in China. Open to male participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-14.
Sponsored by Keymed Biosciences Co.Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single-center, randomized, open-label study to evaluate the pharmacokinetics of CM310 in healthy subjects.
This study includes screening and treatment and follow-up periods.
Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CM310 injection, Subcutaneous
Biological: CM310
CM310 injection, Subcutaneous
Biological: CM310
CM310 injection
Pharmacokinetic: the maximum concentration (Cmax)
Concentration and exposure
Time frame: up to week 6
Start is estimated for Apr 2024; primary completion for Apr 2025, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stapokibart